Novo Nordisk A/S reported share transactions by board members and executives on January 31, 2024, including transfers of shares as part of a Long Term Incentive programme and sales at DKK 756.84 for 2,166 shares. The total reported transactions included over 320,000 shares transferred or sold, all recorded under market regulation.